| (Values in U.S. Thousands) | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -49,940 | -84,500 | -45,430 | -41,910 | -44,350 |
| Net Income Growth | +40.90% | -86.00% | -8.40% | +5.50% | -23.85% |
Cargo Therapeutics Inc (CRGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CARGO Therapeutics Inc. is a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022 and CRG-023. CARGO Therapeutics Inc. is based in San Mateo, California.
Fiscal Year End Date: 12/31